Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canagliflozin Should Have Limitations Based On Renal Function, Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Several advisory committee members on both sides of a 10-5 vote voiced concern about using Janssen’s diabetes drug in patients with moderate renal impairment.

You may also be interested in...

FDA Panel To Weigh Dapagliflozin Bladder Cancer, CV Safety Questions

Endocrinologic and Metabolic Drugs Advisory Committee will revisit concerns first discussed at 2011 meeting about bladder cancer risk with Bristol/AstraZeneca’s diabetes drug. Cardiovascular meta-analysis continues to suggest benefit but FDA questions what to make of “discordant” results from two studies in patients with CV disease.

Eyes On Dainippon’s Phase III Stem Cell Cancer Drug – Japan Earnings Profiles

Japan’s earnings season highlights new R&D and launch strategies for Mitsubishi Tanabe, Astellas and Takeda.

Cardiovascular Uncertainty Accompanies Canagliflozin To Advisory Panel

Janssen’s diabetes therapy also will undergo discussions about renal and bone fracture risks during a Jan. 10 meeting of FDA’s Endocrinologic and Metabolic Drugs Advisory Committee.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts